TABLE 1.
Characteristics of patients with leprosy investigated for AMR from October 2018 to September 2020 in Brazila
| Variable | Total (n = 1,183) | New case (n = 344) | Relapse (n = 305) | Suspected treatment failure (n = 534) |
|---|---|---|---|---|
| Age, yrs, median (IQR) | 47 (37–49) | 48 (35–49) | 50 (39–61) | 46 (37–59) |
| Sex, male, n (%) | 860 (72.7) | 241 (70.1) | 217 (71.1) | 402 (75.3) |
| Region | ||||
| North, n (%) | 309 (26.1) | 79 (23.0) | 79 (25.9) | 151 (28.3) |
| Northeast, n (%) | 192 (16.2) | 65 (18.9) | 35 (11.5) | 92 (17.2) |
| Southeast, n (%) | 407 (34.4) | 137 (39.8) | 125 (41.0) | 145 (27.1) |
| South, n (%) | 138 (11.7) | 31 (9.0) | 46 (15.1) | 61 (11.4) |
| Midwest, n (%) | 137 (11.6) | 32 (9.3) | 20 (6.5) | 85 (16.0) |
| Clinical form, WHO-multibacillary, n (%) | 1017 (86.0) | 223 (64.8) | 278 (91.1) | 516 (96.6) |
| Reaction, yes, n (%) | 421 (35.6) | 90 (26.2) | 102 (33.4) | 229 (42.9) |
| Treatment regimen, WHO-MDT, n (%) | 887 (75.0) | 220 (64.0) | 260 (85.2) | 407 (76.2) |
| Presence of M. leprae DNA, yes, n (%) | 1085 (91.7) | 321 (93.3) | 273 (89.5) | 491 (92.0) |
| Bacilloscopic index, median (IQR) | 3.00 (2.00–4.25) | 3.50 (2.25–4.75) | 2.00 (0.66–3.95) | 3.00 (1.75–4.00) |
a
MDT, multidrug therapy; WHO, World Health Organization; presence of M. leprae DNA detected by PCR; IQR, interquartile range.